- Home
- ENTA vs TKNO Comparison
ENTA vs TKNO Comparison
Compare ENTA & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- TKNO
- Stock Information
- Founded
- ENTA 1995
- TKNO 1996
- Country
- ENTA United States
- TKNO United States
- Employees
- ENTA N/A
- TKNO N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- ENTA Health Care
- TKNO Health Care
- Exchange
- ENTA Nasdaq
- TKNO Nasdaq
- Market Cap
- ENTA 245.4M
- TKNO 244.7M
- IPO Year
- ENTA 2013
- TKNO 2021
- Fundamental
- Price
- ENTA $9.31
- TKNO $7.28
- Analyst Decision
- ENTA Buy
- TKNO Buy
- Analyst Count
- ENTA 3
- TKNO 2
- Target Price
- ENTA $19.67
- TKNO $5.00
- AVG Volume (30 Days)
- ENTA 114.1K
- TKNO 301.1K
- Earning Date
- ENTA 11-25-2024
- TKNO 11-07-2024
- Dividend Yield
- ENTA N/A
- TKNO N/A
- EPS Growth
- ENTA N/A
- TKNO N/A
- EPS
- ENTA N/A
- TKNO N/A
- Revenue
- ENTA $71,960,000.00
- TKNO $36,347,000.00
- Revenue This Year
- ENTA N/A
- TKNO $3.56
- Revenue Next Year
- ENTA $5.14
- TKNO $13.31
- P/E Ratio
- ENTA N/A
- TKNO N/A
- Revenue Growth
- ENTA N/A
- TKNO N/A
- 52 Week Low
- ENTA $8.51
- TKNO $1.16
- 52 Week High
- ENTA $17.80
- TKNO $8.36
- Technical
- Relative Strength Index (RSI)
- ENTA 28.86
- TKNO 57.30
- Support Level
- ENTA $10.84
- TKNO $6.15
- Resistance Level
- ENTA $10.89
- TKNO $8.36
- Average True Range (ATR)
- ENTA 0.49
- TKNO 0.81
- MACD
- ENTA -0.19
- TKNO -0.02
- Stochastic Oscillator
- ENTA 18.18
- TKNO 60.29
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.